| Prev Close | 3.51 |
| Day Low/High | 3.40 / 3.58 |
| 52 Wk Low/High | 1.05 / 4.67 |
| Avg Volume | 925.70K |
| Exchange | NASDAQ |
| Shares Outstanding | 36.99M |
| Market Cap | 129.84M |
| EPS | -1.00 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Verastem To Present Long-Term Follow-Up Data From The DYNAMO™ Study At The 14th International Conference On Malignant Lymphoma
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced long-term follow-up data from the DYNAMO™ study, which met its...
Verastem To Present At The Jefferies 2017 Global Healthcare Conference
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that the company will present at the Jefferies 2017 Global...
Verastem Announces Duvelisib Data Presentations At The 22nd Congress Of The European Hematology Association
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced an abstract featuring long-term follow up data from the DYNAMO®...
Verastem Reports First Quarter 2017 Financial Results
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the first quarter ended March 31, 2017 and...
Verastem Announces Long Term Follow-up Data From The DYNAMO Study Selected For Oral Presentation At The 14th International Conference On Malignant Lymphoma
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that an abstract describing long term follow-up data from the...
Verastem Appoints Eric K. Rowinsky To The Board Of Directors
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Eric K.
Verastem To Present At The 16th Annual Needham Healthcare Conference
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 16 th Annual Needham Healthcare Conference on Tuesday, April 4 th at 3:00 p.
Data On Verastem's Focal Adhesion Kinase Inhibitor Defactinib Presented At The 2017 American Association For Cancer Research Annual Meeting
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of data for its lead focal adhesion kinase (FAK) inhibitor, defactinib, by the Company's...
Verastem Reports Year-End 2016 Financial Results
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2016, and also provided an overview of certain corporate...
Verastem To Host Conference Call On March 23rd To Discuss Fourth Quarter And Full-Year 2016 Financial Results And Recent Highlights
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will host a conference call and webcast on Thursday, March 23, 2017 at 4:30 p.
Verastem To Present At The Oppenheimer 27th Annual Healthcare Conference
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Oppenheimer 27 th Annual Healthcare Conference on Tuesday, March 21 st at 2:10...
Verastem To Present At The 29th Annual ROTH Conference
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 29 th Annual ROTH Conference on Monday, March 13 th at 4:00 p.
Verastem To Present At 19th Annual BIO CEO & Investor Conference
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 19 th Annual BIO CEO & Investor Conference on Tuesday, February 14 th at...
Verastem Announces Dosing Of First Patient In Combination Trial Of Defactinib And Avelumab In Patients With Ovarian Cancer
Verastem, Inc., (NASDAQ:VSTM) today announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's...
Verastem Announces Executive Leadership Appointments And Changes
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced that Hagop Youssoufian, MSc, MD, has been appointed Head of Hematology and Oncology Development.
Verastem Presents Phase 2 DYNAMO® Clinical Data At ASH 2016 Annual Meeting
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of results from the DYNAMO® study, a Phase 2 clinical trial evaluating the safety and efficacy...
Verastem Reports Third Quarter 2016 Financial Results
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the third quarter ended September 30, 2016, and also provided an overview of certain corporate...
Verastem Announces Presentations At ASH Annual Meeting
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that new data for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and...
Verastem Licenses Duvelisib From Infinity Pharmaceuticals
Verastem, Inc. (NASDAQ:VSTM) and Infinity Pharmaceuticals, Inc.
Cancer Research UK, MSD And Verastem Collaborate To Trial New Combination Of Immunotherapy Drugs
CANCER RESEARCH UK has today (Friday) announced its first cross-company deal as part of its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance.
Verastem To Present At Rodman & Renshaw 18th Annual Global Investment Conference
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday,...
Verastem Reports Second Quarter 2016 Financial Results
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the second quarter ended June 30, 2016, and also provided an overview of certain corporate...
Verastem To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Wednesday, July 13th at...
Study Published In Nature Medicine Highlights Potential Role Of FAK Inhibition In Pancreatic Cancer
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the publication of preclinical research in the journal Nature Medicine by the Company's researchers and scientific...
Verastem Announces Changes To Its Board Of Directors
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company's Board of Directors.
Verastem To Present At Upcoming Investor Conferences
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: The Jefferies 2016...
Verastem Reports First Quarter 2016 Financial Results
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the first quarter ended March 31, 2016, and also provided an overview of certain corporate...
